NASDAQ:IRON Disc Medicine Q2 2025 Earnings Report $57.77 -0.02 (-0.03%) Closing price 04:00 PM EasternExtended Trading$57.80 +0.03 (+0.05%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Disc Medicine EPS ResultsActual EPSN/AConsensus EPS -$1.17Beat/MissN/AOne Year Ago EPSN/ADisc Medicine Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADisc Medicine Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Disc Medicine Earnings HeadlinesBristol Myers drug fails main goal in cancer-linked anemia trial2 hours ago | msn.comBristol Myers' drug fails main goal in cancer-related anemia trialJuly 18 at 11:35 AM | msn.comCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. July 18 at 2:00 AM | Timothy Sykes (Ad)Disc Medicine Appoints Nadim Ahmed to its Board of DirectorsJuly 14, 2025 | globenewswire.comMorgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PTJuly 10, 2025 | msn.comDisc Medicine Earns Relative Strength Rating Upgrade; Hits Key ThresholdJuly 9, 2025 | msn.comSee More Disc Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Disc Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Disc Medicine and other key companies, straight to your email. Email Address About Disc MedicineDisc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for disorders of iron dysregulation. Iron homeostasis plays a central role in a broad spectrum of diseases, including iron overload conditions such as hereditary hemochromatosis and iron-restricted anemias driven by chronic inflammation. Disc Medicine applies proprietary antibody discovery platforms to target key proteins involved in iron transport and storage, with the goal of restoring balanced iron levels in patients who suffer from life-threatening complications of iron imbalance. The company’s lead program is an investigational monoclonal antibody that targets ferroportin, the only known cellular iron exporter, to modulate iron egress from cells and reduce systemic iron overload. This candidate, currently in early-stage clinical studies, is being evaluated for safety, tolerability and preliminary signs of activity in patients with hereditary and secondary iron overload. In parallel, Disc Medicine is advancing a second antibody program designed to neutralize hepcidin, the master regulator of iron sequestration, with the aim of alleviating anemia of inflammation in chronic disease settings. Headquartered in South San Francisco, Disc Medicine was founded by a multidisciplinary team of scientists and clinicians with deep expertise in iron biology, antibody engineering and translational medicine. The company completed its initial public offering in 2022 and trades on the Nasdaq under the ticker IRON. Disc Medicine continues to expand its research capabilities, forging collaborations with academic centers and patient-advocacy groups to support the development of therapies for underserved populations affected by iron dysregulation disorders.Written by Jeffrey Neal JohnsonView Disc Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
